RxDoctor Payments Data

Deborah Smith, MD

Family Medicine · Jim Thorpe, PANPI 1154382604

Payments from drug & device makers

$2,846in general payments, 2019–2025

Across 190 payments — averaging $14.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$681
  • AstraZeneca$378
  • Pfizer$328
  • Boehringer Ingelheim$261
  • Lilly USA, LLC$250
  • GSK$221
  • plus $728 from 15 others

What the payments were for

  • Food & beverage$2,846100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,846 in reported general payments places this provider in the 80th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$198,411
Medicare patients
310
Services billed
4,323

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide78$108,754
EliquisApixaban108$91,578
JardianceEmpagliflozin66$47,641
FarxigaDapagliflozin Propanediol45$35,996
XareltoRivaroxaban31$25,733
TrulicityDulaglutide19$21,950
JanuviaSitagliptin Phosphate22$18,950
RybelsusSemaglutide17$17,111
TradjentaLinagliptin21$16,155
Breo ElliptaFluticasone/Vilanterol24$12,941
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$10,978
MyrbetriqMirabegron16$9,372
OxycontinOxycodone Hcl19$7,639
Janumet XrSitagliptin Phos/Metformin Hcl13$7,326
Levothyroxine Sodium498$4,536

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$681$125,86595 claims
PfizerEliquis$328$91,578108 claims
Boehringer IngelheimJardiance, Tradjenta$261$63,79687 claims
AstraZenecaFarxiga$378$35,99645 claims
MerckJanuvia, Janumet Xr$176$26,27635 claims
Johnson & JohnsonXarelto$11$25,73331 claims
GSKBreo Ellipta, Trelegy Ellipta$221$23,92040 claims
Lilly USA, LLCTrulicity$250$21,95019 claims
AbbVieSynthroid$205$3,86855 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Jim Thorpe

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →